{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:03:14Z","timestamp":1785402194964,"version":"3.56.0"},"reference-count":36,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"University of Texas Medical Branch, Department of Microbiology and Immunology"},{"DOI":"10.13039\/100000016","name":"US Department of Health and Human Services","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"crossref"}]},{"id":[{"id":"https:\/\/ror.org\/05p26gw61","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"NIH","doi-asserted-by":"publisher","award":["UC7AI094660"],"award-info":[{"award-number":["UC7AI094660"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"award":["UC7AI094660"],"award-info":[{"award-number":["UC7AI094660"]}],"id":[{"id":"https:\/\/ror.org\/044zkrt47","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>Lujo virus (LUJV) is an arenavirus that causes Lujo Hemorrhagic Fever (LHF), a viral hemorrhagic fever that emerged in a 2007 outbreak in Zambia and South Africa with an 80% case fatality rate and evidence of human-to-human nosocomial transmission. There are no approved medical countermeasures for LHF, although several screens have identified lead antiviral compounds. The lack of accessible animal models limits the development of lead compounds and characterization of broadly protective anti-arenavirus compounds such as ribavirin for the treatment of LHF. Here, we present preliminary data characterizing the partially lethal disease caused by LUVJ in STAT-1 deficient mice. Several key hematological, clinical chemistry, and histologic findings common to LHF disease are recapitulated in this model. This work suggests that further characterization of LUJV infection in STAT-1 deficient mice may allow development of a model that would be instrumental in the development of medical countermeasures for LHF.<\/jats:p>","DOI":"10.3390\/pathogens15040394","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T08:09:00Z","timestamp":1775549340000},"page":"394","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hemorrhagic Fever Disease in STAT-1 Knockout Mice Infected with Lujo Virus"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3630-0588","authenticated-orcid":false,"given":"Dylan M.","family":"Johnson","sequence":"first","affiliation":[{"name":"Texas Biomedical Research Institute, San Antonio, TX 78227, USA"},{"name":"Sandia National Laboratories, Livermore, CA 94550, USA"},{"name":"Galveston National Laboratory, Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Jan","sequence":"additional","affiliation":[{"name":"Sandia National Laboratories, Livermore, CA 94550, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8608-0051","authenticated-orcid":false,"given":"Ethan","family":"Dunn","sequence":"additional","affiliation":[{"name":"Sandia National Laboratories, Livermore, CA 94550, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason E.","family":"Comer","sequence":"additional","affiliation":[{"name":"Galveston National Laboratory, Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Cross","sequence":"additional","affiliation":[{"name":"Galveston National Laboratory, Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0858-1877","authenticated-orcid":false,"given":"Thomas W.","family":"Geisbert","sequence":"additional","affiliation":[{"name":"Galveston National Laboratory, Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Briese, T., Paweska, J.T., McMullan, L.K., Hutchison, S.K., Street, C., Palacios, G., Khristova, M.L., Weyer, J., Swanepoel, R., and Egholm, M. (2009). Genetic Detection and Characterization of Lujo Virus, a New Hemorrhagic Fever\u2013Associated Arenavirus from Southern Africa. PLoS Pathog., 5.","DOI":"10.1371\/journal.ppat.1000455"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.3201\/eid1510.090211","article-title":"Nosocomial Outbreak of Novel Arenavirus Infection, Southern Africa","volume":"15","author":"Paweska","year":"2009","journal-title":"Emerg. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"748","DOI":"10.7196\/SAMJnew.8330","article-title":"Viral Haemorrhagic Fevers in South Africa: Review","volume":"105","author":"Richards","year":"2015","journal-title":"S. Afr. Med. J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ijid.2014.08.015","article-title":"The Efficacy of Ribavirin in Crimean-Congo Hemorrhagic Fever\u2014Randomized Trials Are Urgently Needed","volume":"29","author":"Ceylan","year":"2014","journal-title":"Int. J. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ijid.2014.08.016","article-title":"Evidence Supports Ribavirin Use in Crimean-Congo Hemorrhagic Fever","volume":"29","author":"Ergonul","year":"2014","journal-title":"Int. J. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Salam, A.P., Duvignaud, A., Jaspard, M., Malvy, D., Carroll, M., Tarning, J., Olliaro, P.L., and Horby, P.W. (2022). Ribavirin for Treating Lassa Fever: A Systematic Review of Pre-Clinical Studies and Implications for Human Dosing. PLoS Neglected Trop. Dis., 16.","DOI":"10.1371\/journal.pntd.0010289"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.coviro.2020.06.011","article-title":"Reverse Genetics Approaches for the Development of Mammarenavirus Live-Attenuated Vaccines","volume":"44","author":"Ye","year":"2020","journal-title":"Curr. Opin. Virol."},{"key":"ref_8","unstructured":"Paweska, J.T., van Vuren, P.J., and Weyer, J. (2016). 16 Lujo Virus Hemorrhagic Fever. Viral Hemorrhagic Fevers, Springer."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.chom.2017.10.002","article-title":"NRP2 and CD63 Are Host Factors for Lujo Virus Cell Entry","volume":"22","author":"Raaben","year":"2017","journal-title":"Cell Host Microbe"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/s41564-018-0224-5","article-title":"Structural Basis for Receptor Recognition by Lujo Virus","volume":"3","author":"Kilimnik","year":"2018","journal-title":"Nat. Microbiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e03060-21","DOI":"10.1128\/mbio.03060-21","article-title":"Molecular Mechanisms Underlying the Cellular Entry and Host Range Restriction of Lujo Virus","volume":"13","author":"Saito","year":"2022","journal-title":"Mbio"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.3201\/eid1710.10452","article-title":"Novel Arenavirus, Zambia","volume":"17","author":"Ishii","year":"2011","journal-title":"Emerg. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1099\/vir.0.044099-0","article-title":"Molecular Surveillance and Phylogenetic Analysis of Old World Arenaviruses in Zambia","volume":"93","author":"Ishii","year":"2012","journal-title":"J. Gen. Virol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Moonga, L.C., Chipinga, J., Collins, J.P., Kapoor, V., Saasa, N., Nalubamba, K.S., Hang\u2019ombe, B.M., Namangala, B., Lundu, T., and Lu, X.-J. (2024). Application of a Sensitive Capture Sequencing Approach to Reservoir Surveillance Detects Novel Viruses in Zambian Wild Rodents. Viruses, 16.","DOI":"10.3390\/v16111754"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"293","DOI":"10.30802\/AALAS-JAALAS-18-000118","article-title":"Hematology and Clinical Chemistry Reference Intervals for Inbred Strain 13\/N Guinea Pigs (Cavia porcellus)","volume":"58","author":"Genzer","year":"2019","journal-title":"J. Am. Assoc. Lab. Anim. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"416","DOI":"10.4269\/ajtmh.1987.36.416","article-title":"Studies of the Coagulation System in Arenaviral Hemorrhagic Fever: Experimental Infection of Strain 13 Guinea Pigs with Pichinde Virus","volume":"36","author":"Cosgriff","year":"1987","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1128\/JVI.02246-14","article-title":"Delayed Inflammatory and Cell Death Responses Are Associated with Reduced Pathogenicity in Lujo Virus-Infected Cynomolgus Macaques","volume":"89","author":"Rasmussen","year":"2015","journal-title":"J. Virol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1128\/JVI.02948-15","article-title":"Animal Model of Sensorineural Hearing Loss Associated with Lassa Virus Infection","volume":"90","author":"Yun","year":"2016","journal-title":"J. Virol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Johnson, D.M., Jokinen, J.D., and Lukashevich, I.S. (2019). Attenuated Replication of Lassa Virus Vaccine Candidate ML29 in STAT-1-\/- Mice. Pathogens, 8.","DOI":"10.3390\/pathogens8010009"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Johnson, D.M., Cubitt, B., Pfeffer, T.L., de La Torre, J.C., and Lukashevich, I.S. (2021). Lassa Virus Vaccine Candidate ML29 Generates Truncated Viral RNAs Which Contribute to Interfering Activity and Attenuation. Viruses, 13.","DOI":"10.3390\/v13020214"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1186\/1743-422X-8-300","article-title":"A STAT-1 Knockout Mouse Model for Machupo Virus Pathogenesis","volume":"8","author":"Bradfute","year":"2011","journal-title":"Virol. J."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Monticelli, S.R., Kuehne, A.I., Bakken, R.R., Coyne, S.R., Lewis, K.D., Raymond, J.L.W., Zeng, X., Richardson, J.B., Lapoint, Z., and Williams, J.L. (2025). Characterization of a STAT-1 Knockout Mouse Model for Machupo Virus Infection and Pathogenesis. Viruses, 17.","DOI":"10.3390\/v17070996"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1128\/JVI.06284-11","article-title":"Functional Interferon System Is Required for Clearance of Lassa Virus","volume":"86","author":"Yun","year":"2012","journal-title":"J. Virol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Rieger, T., Merkler, D., and G\u00fcnther, S. (2013). Infection of Type I Interferon Receptor-Deficient Mice with Various Old World Arenaviruses: A Model for Studying Virulence and Host Species Barriers. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0072290"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"13063","DOI":"10.1128\/JVI.01389-10","article-title":"Mice Lacking Alpha\/Beta and Gamma Interferon Receptors Are Susceptible to Junin Virus Infection","volume":"84","author":"Kolokoltsova","year":"2010","journal-title":"J. Virol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Gowen, B.B., Wong, M.-H., Larson, D., Ye, W., Jung, K.-H., Sefing, E.J., Skirpstunas, R., Smee, D.F., Morrey, J.D., and Schneller, S.W. (2010). Development of a New Tacaribe Arenavirus Infection Model and Its Use to Explore Antiviral Activity of a Novel Aristeromycin Analog. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0012760"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1586\/erv.12.139","article-title":"The Search for Animal Models for Lassa Fever Vaccine Development","volume":"12","author":"Lukashevich","year":"2013","journal-title":"Expert Rev. Vaccines"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.coviro.2013.04.007","article-title":"Vaccines for Viral Hemorrhagic Fevers\u2014Progress and Shortcomings","volume":"3","author":"Falzarano","year":"2013","journal-title":"Curr. Opin. Virol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"10759","DOI":"10.1128\/JVI.01144-12","article-title":"Reverse Genetics Recovery of Lujo Virus and Role of Virus RNA Secondary Structures in Efficient Virus Growth","volume":"86","author":"Bergeron","year":"2012","journal-title":"J. Virol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Cao, J., Dong, S., Liu, Y., Zhou, M., Guo, J., Jia, X., Zhang, Y., Hou, Y., Tian, M., and Xiao, G. (2021). Screening and Identification of Lujo Virus Entry Inhibitors from an Food and Drug Administration-Approved Drugs Library. Front. Microbiol., 12.","DOI":"10.3389\/fmicb.2021.793519"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Welch, S.R., Spengler, J.R., Genzer, S.C., Chatterjee, P., Flint, M., Bergeron, \u00c9., Montgomery, J.M., Nichol, S.T., Albari\u00f1o, C.G., and Spiropoulou, C.F. (2021). Screening and Identification of Lujo Virus Inhibitors Using a Recombinant Reporter Virus Platform. Viruses, 13.","DOI":"10.3390\/v13071255"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e867","DOI":"10.1093\/infdis\/jiaf081","article-title":"Natural History of Chapare Virus Infection in Strain 13 Guinea Pigs","volume":"231","author":"Johnson","year":"2025","journal-title":"J. Infect. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Comer, J.E., Escaffre, O., Neef, N., Brasel, T., Juelich, T.L., Smith, J.K., Smith, J., Kalveram, B., Perez, D.D., and Massey, S. (2019). Filovirus Virulence in Interferon \u03b1\/\u03b2 and \u03b3 Double Knockout Mice, and Treatment with Favipiravir. Viruses, 11.","DOI":"10.3390\/v11020137"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Jung, S.R., Ashhurst, T.M., West, P.K., Viengkhou, B., King, N.J., Campbell, I.L., and Hofer, M.J. (2020). Contribution of STAT1 to Innate and Adaptive Immunity during Type I Interferon-Mediated Lethal Virus Infection. PLoS Pathog., 16.","DOI":"10.1371\/journal.ppat.1008525"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Tailor, N., Pr\u00e9vost, J., Soule, G., Deschambault, Y., Sloan, A., Chan, M., and Safronetz, D. (2025). Age-and Sex-Associated Differences in Lujo Hemorrhagic Fever Pathogenesis in Strain 13\/N Guinea Pigs. PLoS Neglected Trop. Dis., 19.","DOI":"10.1371\/journal.pntd.0013633"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12985-025-02669-y","article-title":"Lassa Virus Protein\u2013Protein Interactions as Mediators of Lassa Fever Pathogenesis","volume":"22","author":"Jan","year":"2025","journal-title":"Virol. J."}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/15\/4\/394\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T04:22:21Z","timestamp":1775708541000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/15\/4\/394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":36,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["pathogens15040394"],"URL":"https:\/\/doi.org\/10.3390\/pathogens15040394","relation":{},"ISSN":["2076-0817"],"issn-type":[{"value":"2076-0817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,7]]}}}